ID: MRFR/MED/0682-HCR | 80 Pages | Published By Kinjoll Dey on March 2023
The Asia Pacific Interventional Cardiology Market for this is expected to reach USD 2790.60 Million by the end of the forecasted period growing at a CAGR of 8%.
Asia pacific interventional cardiology market is anticipated to reach USD 2790.60 Million by 2030 at 8% CAGR during the forecast period 2022-2030
Interventional cardiology is a branch of cardiology that deals with catheter based treatment for heart diseases. By catheterization, number of procedures can be performed on the heart. According to International Diabetes Federation, 60% of world’s total diabetic population lives in Asia. Diabetic is one of the major factors which lead to cardiovascular diseases. Increasing prevalence of cardiovascular diseases is the major factor for the growth of the market in Asia Pacific. Beside this increasing incidences of diabetes and obesity, change in lifestyle, increasing awareness among the people and rapid development in technology also contributed to the growth of the market. On other hand, high cost for manufacturing the devices and lot of barriers for the development of the new device are the major restraints hampering the market growth.
Figure 1- Asia Pacific interventional cardiology market, by application
Sources- Annual reports, White paper, Company Presentation
Asia Pacific interventional cardiology market is segmented on the basis of type, into catheters, stents, balloons, vascular closure devices, laser procedures, atherectomy and other. Stents are sub segmented into metal stents, drug eluting stents and bioresorbable stents. Balloons are further segmented into cutting balloons, drug eluting balloons and other. On the basis of end users the Asia Pacific interventional cardiology market is segmented into catheterization laboratories, hospitals and clinics and others
On the basis of region, Asia Pacific interventional cardiology market is segmented into countries namely Japan, India, China, Australia, Republic of Korea and Rest of Asia Pacific. China accounts for the largest market share which is attributed to an increase in incidence of chronic heart diseases, increasing geriatric population, and demand for early diagnosis of cardiac disease. India holds the second largest market whereas Japan shows steady growth in this market.
Key Players for Asia Pacific interventional cardiology market
Abbott Laboratories Inc. (U.S.), B. Braun Melsungen AG (Germany), C.R. Bard, Inc. (U.S.), Abiomed Inc. (U.S), Edwards Lifesciences (U.S.), Biosensors International Group, Ltd. ( Singapore), Boston Scientific Corporation (U.S.), Medtronic PLC (Ireland), Angiodynamics, Inc. ( U.S), Terumo Medical Corporation (Japan), Johnson & Johnson Services, Inc. (U.S.)., Lombard Medical Technologies, Plc. (U.K), Clearstream Technologies Group Plc. (Ireland).
Study objectives Asia Pacific interventional cardiology market
The report for Asia Pacific interventional cardiology market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.